We are pleased to partner with AFUF for our 1st Annual European Congress on Genitourinary Malignancies™, where GU cancers have rapidly changed over the past few years. - Phil Talamo
Cranbury, NJ (PRWEB) March 21, 2017
Physicians’ Education Resource®, LLC (PER®), is collaborating with the Association of Young Urologists in France (AFUF) for PER®’s 1stAnnual European Congress on Genitourinary (GU) Malignancies™ on June 23-24, 2017, in Prague, Czech Republic, announced Phil Talamo, president of PER®.
In making the announcement, Talamo said, “We are pleased to collaborate with AFUF for our 1st Annual European Congress on Genitourinary Malignancies™, where GU cancers have rapidly changed over the past few years with new therapies and multidisciplinary care remains critical in optimizing patient outcomes.”
In this collaboration, AFUF will promote PER’s® Annual European Congress on Genitourinary Malignancies through multiple channels in their membership. Additionally, AFUF members will receive a special discount to attend the Congress, but still need to register.
The 1st Annual European Congress on Genitourinary Malignancies™ is a practical and interactive multiday program that features a faculty of leading international experts who will provide the latest information and guidance. The format will allow participants to engage with faculty in a direct exchange of perspectives, personal experiences and strategies related to clinical challenges in the management of GU cancers.
The event will take place at the Grand Majestic Plaza Hotel, Czech Republic. For more information or to register, please visit: http://www.gotoper.com/go/AFUF
Since 1995, PER® has been the educational resource of choice for live and online activities focusing on oncology and hematology. PER® provides high-quality, evidence-based activities featuring leading national and international faculty with a focus on practice-changing advances and standards of care in treatment and disease management. Activities also include topics on emerging strategies currently under investigation, supportive care, diagnosis and staging, prevention, screening and early detection, and practice management. With the rapid advances occurring in the field of oncology, understanding how to use molecular data to diagnose and stage patients, selecting the most appropriate candidates for novel therapeutic agents, individualizing treatment based on tumor type, and referring patients to clinical trials will continue to ensure the highest level of patient care is provided. PER® serves the oncology health care community, including physicians, fellows, advanced practice nurses, nurses, physician assistants, pharmacists, and researchers. PER® is part of the Cranbury, N.J.-based Michael J. Hennessy Associates, Inc. family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com